{"name":"Avistone Biotechnology Co., Ltd.","slug":"avistone-biotechnology-co-ltd","ticker":"","exchange":"","domain":"avistonebiotechnology.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ANS014004","genericName":"ANS014004","slug":"ans014004","indication":"Other","status":"phase_1"},{"name":"ANS03","genericName":"ANS03","slug":"ans03","indication":"Other","status":"phase_1"},{"name":"PLB1004","genericName":"PLB1004","slug":"plb1004","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Pemetrexed plus Carboplatin or Cisplatin","genericName":"Pemetrexed plus Carboplatin or Cisplatin","slug":"pemetrexed-plus-carboplatin-or-cisplatin","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_3"}]}],"pipeline":[{"name":"ANS014004","genericName":"ANS014004","slug":"ans014004","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ANS03","genericName":"ANS03","slug":"ans03","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PLB1004","genericName":"PLB1004","slug":"plb1004","phase":"phase_3","mechanism":"PLB1004 is a small molecule inhibitor targeting a specific molecular pathway in cancer or immune-related disease.","indications":[],"catalyst":""},{"name":"Pemetrexed plus Carboplatin or Cisplatin","genericName":"Pemetrexed plus Carboplatin or Cisplatin","slug":"pemetrexed-plus-carboplatin-or-cisplatin","phase":"phase_3","mechanism":"Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, while carboplatin or cisplatin are platinum-based agents that cross-link DNA, together inducing cancer cell death.","indications":["Non-small cell lung cancer (NSCLC)","Mesothelioma","Other solid tumors (phase 3 dependent)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxQMjdoWDhBZTZ4UnllR2p3Qjdqa2JRUVc5X09BLWo4a21QdW9NQkJVZ3ZmVVpTT1FxbXdLa2loN1RqSU5QUl9Nc0s0ZTlCU2xnZ19acDhqUlFrdFFFTjZMV3hQTmQ2d2IzUW5lMmhvODRXNlJWcjhPUTFld1hyakQ5NGwwZ3RSeFpOTHZVRTY0WEktUU1qREVSNmRmVFZkRUxFaFdOM0pSbktROXFfRkF4T1pPZllaQUtMTFZQUXRfY1RPMXZjVmd3UTFHMjFHcHpXOTZFckJBckYxNTU1c1NhVVQzRW9JaV9JTUVYT2l3QkJvclVzVWhScHBXdjNIQ1NPWFZKUTJ4UW1hRUhpcVJlNEUyWUFzT3JuSE9QdjRvODNrYVN1SzE3WnkxOGJlUWV4ZzRiWUVPeW1lUjJkZ2tVem1VQQ?oc=5","date":"2026-04-02","type":"pipeline","source":"globenewswire.com","summary":"Low-Grade Glioma Market Trends and Investment Opportunities - globenewswire.com","headline":"Low-Grade Glioma Market Trends and Investment Opportunities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPUjc5LVJ4dnJkdWdPVElCNjY3SnBHWUV1WHI1akpCRE44WnFTN2k0ckFjeG52Y2lhQzN6bjByMXpOU3hHUjBfVkxFSUpjN2xZSXhiaExGR2JoYnJIUWFTSUZZelcxZEFqd0JmNW9uVWtvN1dWV19vcFk3Y3dKQ2JqODR1d0hwRHVPWHFiMTAxX1JDUGc1VWFnLUZWNA?oc=5","date":"2026-03-24","type":"pipeline","source":"openPR.com","summary":"EGFR Non Small Cell Lung Cancer Pipeline 2026: Key Companies, - openPR.com","headline":"EGFR Non Small Cell Lung Cancer Pipeline 2026: Key Companies,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOWi1mY3E1LXBUaC1XMURMYl9uOWg3dFRtZjJDWDlhZXIzbFpaS1FETjdETHlXdW9mbEd0SlpNb0ViN2M1LUdRbzdCSWRkYkhiYzB4VjBDbnp5ZlZZTElMcUNSMG12Sk5RMEFmTGRKelVRNUttQmZnSU5xaXE4Q1RvalZVRzNnQQ?oc=5","date":"2025-10-28","type":"pipeline","source":"Labiotech.eu","summary":"10 biotech companies in China you should know about - Labiotech.eu","headline":"10 biotech companies in China you should know about","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNRFJkZUJQLXVYVjQxQ3k3MUVyakctSHlVVFRTUDh0RTdaM1VIXzl2Nk1CWXptNl8ydWJkNDB6U05EemVoMlVNNzFSeUptSnRmdldYYnl1b182Y2QxYnQtRWlKaXV5UVVzQTg0SnItZ19ZU0FXN3A4OE41SHlyRUE0Sm9ya01US1RfVm1INWlsVzl0M3lwQ2dKZVVCTGpjdlF5bVdEdVM0UmZIUmVnNzN6NjVBNFlYTjNpbF9JSVBnMnJJZWJCSzNhTDdCUURGbTdNU0xoa2JsNFJHUzAwOXdSOHZRT21pbHoyLXE1UzdmeEFwUGxTWVROZXJrYjB5QQ?oc=5","date":"2025-10-14","type":"pipeline","source":"Quiver Quantitative","summary":"Apollomics Inc. Provides Operational Update and Reaffirms Commitment to APL-101 Development Following Leadership Changes and New Funding - Quiver Quantitative","headline":"Apollomics Inc. Provides Operational Update and Reaffirms Commitment to APL-101 Development Following Leadership Changes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxNbGJybkVpUkdMRmxWWkJ0dW5vUnk5LVdLNmxmREtILXowYXNYZjBMN2ZEQmYxYzdGN05VWkF0bXR3ZU1yTGtOTWctNkZaQ0Y1ZWNKTjE1S091Mm94NHdiekNvelRNLWFSV2lmbzlJSVFzei1KM0haR2F2eXBValZLbU5GQV81TjA1ZGpqTnFMbWUzU3lyQ2dVNng2dlBhZkc4TnhHRXhPcE9UVDlScHFONklXMWM5dGJLQVVOVW5KUkNaS2xrc2NWRlNfUlF4em5hSEl0SXVXUWRXTzRvWUJISHhZWDEtTzBvdVhPYlRzeXo3anlGLURfVlVUdkJsd184c2cxX05COFdMMVJ3SXJiUmdKanhhWWxfWTQtTi1BMDliV2JaYlhjbW5JaDVGQXgxa2dIT1NR?oc=5","date":"2025-06-02","type":"pipeline","source":"BioSpace","summary":"Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025 - BioSpace","headline":"Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplif","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQeXJqTkVUdXA2LU9pbXEtVlBlVXJhck9tWkttcUtHZGpOS2ZMeWFFNUZ4NlpTRUU1UGRWbjJFd1cwS2U4dkVrQV94Mnh5Q19pR1hTVk5yRjN5N001ODlleXdBRHBtVDJSanlwNVZtUjgtQlp3T05GRENGLWNMS2cyMg?oc=5","date":"2024-12-05","type":"pipeline","source":"BioSpace","summary":"Avistone Announces Updates on ANS03 - BioSpace","headline":"Avistone Announces Updates on ANS03","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNTzBFX19nZG1IVjFSSDBmWHZBWS1qbkE1TEgxVnlkQlFuWm1oNEJkV0dQeFJoa0hEd2xyS3ZhMkhmWTBPVldJVXllbEpQc0xJVnZLUnVGTThQeHBJTXhzRHU1MVlVbEVELUw3MG9YYjlQU2J4SUlIc1NJbUg3Slc4M3VVZUJid0tqT1FHQ3lqX29SYXhzTFpNRkNiZlE?oc=5","date":"2024-10-04","type":"pipeline","source":"Business Wire","summary":"Avistone Announces Updates on ANS014004 - Business Wire","headline":"Avistone Announces Updates on ANS014004","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1LbjhaVFFFSnA5enVJaGVtVDhiRHQ3NE15NmlTOU90bTRSdm1TMG51T0lCX0RBUm9na3owdlQ1UWtCeEVmX1Aybmd0ekJ0dmJvdmx0c2xMbk1FMU5tWGhodTJidnVnS2tTYVhOeWNXYXR4Sk10Z0hHczRPVQ?oc=5","date":"2024-01-05","type":"pipeline","source":"Pharmaceutical Technology","summary":"Avistone raises $140m to support drug research and development - Pharmaceutical Technology","headline":"Avistone raises $140m to support drug research and development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdGNsWXFranRzcE9qTnl4bjRwTlVJYllrLXpiYTdGb2VyOE5FVjVoT2NvZnhxWEpyc1JmT0ljTkItUm1NZkpQTGZGdWl0M2ZMRUdoaDN3bk81WDdhckMtRm4tdThKclRhNm1TOGJRbnZuMmRQa2hrMEk1T0xrZTg4NWlVSDdkQVJ0b183WTRGVE9VU2JhOXg5UVczQ05SeXpucFJQRUJLS2U5N1NpOWVmYmtsUnFOSWs4RzBn?oc=5","date":"2024-01-04","type":"pipeline","source":"Business Wire","summary":"Avistone Biotechnology Announces Closing of Series B Financing - Business Wire","headline":"Avistone Biotechnology Announces Closing of Series B Financing","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":2,"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}